AKUMS750.00

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹11,483 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
AKUMS
FY26
ALIVUS
FY24
AGARWALEYE
FY26
ADVENZYMES
FY26
Peer
Median
Valuation — at last close
P/E44.99×118.81×20.04×69.43× -35%
P/B3.45×7.48×2.01×4.74× -27%
EV/EBITDA21.40×27.67×11.83×19.75× +8%
Market Cap₹11,483 Cr₹15,846 Cr₹3,382 Cr₹9,614 Cr +19%
Growth
Revenue CAGR 3Y11.32%11.32%
Revenue CAGR 5Y8.24%8.24%
Net Income CAGR 3Y18.68%18.68%
Revenue YoY (latest Q)13.93%25.97%2.08%14.02% -1%
Net Income YoY (latest Q)56.11%44.56%-4.58%19.99% +181%
Profitability
EBITDA Margin11.98%29.53%27.38%30.72%29.53% -59%
Net Income Margin5.88%20.62%8.08%23.28%20.62% -71%
Return on Common Equity7.66%20.19%6.28%10.02%10.02% -24%
Return on Capital Employed8.44%25.74%8.43%10.91%10.91% -23%
Return on Assets4.71%16.52%4.27%9.44%9.44% -50%
Credit & Quality
Total Debt/Equity0.02×0.07×0.01×0.04× -50%
Interest Coverage3.91×401.55×3.24×71.91×71.91× -95%
Scale — latest FY
Revenue / Total Income₹4,359 Cr₹2,283 Cr₹2,080 Cr₹746 Cr₹2,080 Cr +110%
Net Income₹256 Cr₹471 Cr₹168 Cr₹174 Cr₹174 Cr +48%
Total Assets₹5,447 Cr₹2,850 Cr₹3,942 Cr₹1,839 Cr₹2,850 Cr +91%
EPS₹16.67₹4.21₹15.08₹9.65 +73%
Book Value per Share₹217.57₹66.91₹150.38₹108.65 +100%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.